{
    "clinical_study": {
        "@rank": "11540", 
        "arm_group": {
            "arm_group_label": "MSC2156119J", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of\n      MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy\n      or to which no effective standard therapy is applicable."
        }, 
        "brief_title": "A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A subject with a histologically or cytologically confirmed diagnosis of malignant\n             solid tumor which is refractory to standard therapy or to which no effective standard\n             therapy is applicable\n\n          -  An archived tumor tissue is available or biopsy of tumor tissues can be newly\n             performed\n\n          -  A Japanese male or female, age greater than or equal to 20 years\n\n          -  A subject who has read the Subject Information Sheet and understood the details of\n             this clinical trial, and is willing and able to give his/her informed consent.\n\n          -  A female of child-bearing potential must have a negative blood pregnancy test result\n             at her screening period. A female subject of child-bearing potential must be willing\n             to avoid pregnancy by using an adequate method of contraception Life expectancy is at\n             least 3 months\n\n          -  Other inclusion criteria apply\n\n        Exclusion Criteria:\n\n          -  Known Human immunodeficiency virus (HIV) positivity, active hepatitis C, or active\n             hepatitis B\n\n          -  Presence of liver fibrosis or liver cirrhosis that has been histologically diagnosed\n\n          -  Signs or symptoms that suggest transmissible spongiform encephalopathy\n\n          -  Received major surgery within 6 weeks before Day 1 in Cycle 1\n\n          -  Known drug abuse or alcohol abuse\n\n          -  Known hypersensitivity to any of the trial treatment ingredients\n\n          -  Hematological test abnormalities\n\n          -  Renal impairment as defined in the protocol\n\n          -  Liver dysfunction as defined in the protocol\n\n          -  History or presence of central nervous system metastasis\n\n          -  History or presence of disease or condition that may hamper compliance or absorption\n             of the investigational medicinal product (IMP) due to difficulty in swallowing or\n             absorption\n\n          -  Poor performance status of Eastern Cooperative Oncology Group Performance status\n             (ECOG PS) greater than or equal to 2\n\n          -  Received any anti-cancer therapy days Received extensive prior radiotherapy that\n             irradiates more than 30 percent of bone marrow\n\n          -  Received any radiotherapy within 4 weeks before Day 1 in Cycle 1\n\n          -  Pregnancy and lactation period\n\n          -  History of receiving treatment with any c-Met signaling pathway inhibitor\n\n          -  Participation in another interventional clinical trial within the past 30 days from\n             Day 1 in Cycle 1\n\n          -  Other significant disease that in the Investigator's opinion would exclude the\n             subject from the trial\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Other exclusion criteria apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832506", 
            "org_study_id": "EMR 200095-003"
        }, 
        "intervention": {
            "arm_group_label": "MSC2156119J", 
            "description": "MSC2156119J will be administered in the assigned doses in combinations of 15 milligram (mg) and/or 100 mg capsules orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.", 
            "intervention_name": "MSC2156119J", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Solid Tumors", 
            "MSC2156119J", 
            "c-Met inhibitor", 
            "Japanese", 
            "Phase 1"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors", 
        "overall_contact": {
            "email": "service@merck.de", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Serono Co., Ltd., Japan", 
            "last_name": "Kotaro Funato", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects experiencing Dose Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "up to Day 21 of Cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832506"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with Treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 30 after the last day of study treatment"
            }, 
            {
                "measure": "Pharmacokinetic parameters: Cmax, tmax, t1/2, AUC, CL/f, V(z)/f, V(ss)/f of MSC2156119J post-administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 2, 3, 8, 14, 15 and 17 of Cycle 1, and Day 1 and 14 of Cycle 2, and Day 1 of Cycle 3 and 4"
            }, 
            {
                "description": "Pharmacodynamic and circulating biomarkers such as hepatocellular growth factor will be measured in blood and proximal Pharmacodynamic biomarkers such as total c-Met or phospho-c-Met will be measured in tumor tissue.", 
                "measure": "Pharmacodynamic markers levels in blood and tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 2, 3, 8, 14, 15 and 17 of Cycle 1, and Day 1 and 14 of Cycle 2, and Day 1 of Cycle 3 and 4"
            }, 
            {
                "description": "Number of subjects with Clinical Benefit is defined as subjects with Complete response (CR) or Partial response (PR), at any time point or stable disease at week 12 or later, based on tumor assessment as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) .", 
                "measure": "Number of subjects with Clinical Benefit", 
                "safety_issue": "No", 
                "time_frame": "Baseline until the date of first documented progression, up to Day 30 after the last day of study treatment"
            }, 
            {
                "measure": "Progression-free survival time", 
                "safety_issue": "No", 
                "time_frame": "Baseline until first observation of progressive disease, or death  within  12 weeks  of  the  last  tumor  assessment or first administration of MSC2156119J, up to Day 30 after the last day of study treatment"
            }, 
            {
                "measure": "Correlation between c-Met over-expression, amplification and mutation in tumor tissue and  hepatocellular growth factor (HGF)  levels in  plasma, and tumor response to MSC2156119J treatment", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}